Millar J W, Hunter A M, Horne N W
Thorax. 1980 Nov;35(11):856-8. doi: 10.1136/thx.35.11.856.
Twenty-one patients with proven recurrent malignant pleural effusions were randomly allocated to treatment groups receiving either intrapleural Corynebacterium parvum in a dose of 7 mg or intrapleural mustine (20 mg). The designated intrapleural therapy was repeated on one occasion if further pleural aspiration was required. Corynebacterium parvum (nine patients) proved superior to mustine (12 patients) in suppressing the reaccumulation of pleural fluid, and was associated with only minimal side-effects of fever and nausea in two patients. Mustine caused marked nausea and vomiting in almost all patients. Three of the four patients who were deemed "failures" after mustine therapy had complete suppression of pleural fluid reaccumulation after a single dose of C parvum, the survival of the fourth being too short to assess a response adequately. There were no failures in the C parvum treated group. Corynebacterium parvum appears to be an effective, well-tolerated agent in the management of recurrent pleural effusions. The relative contribution of its potent immunological stimulant effect to its mode of action remains uncertain.
21例确诊为复发性恶性胸腔积液的患者被随机分配至治疗组,分别接受7毫克剂量的胸膜内短小棒状杆菌治疗或20毫克的胸膜内氮芥治疗。如果需要进一步胸腔穿刺抽吸,则重复指定的胸膜内治疗一次。在抑制胸腔积液再积聚方面,短小棒状杆菌(9例患者)被证明优于氮芥(12例患者),且仅在2例患者中伴有低热和恶心等轻微副作用。氮芥在几乎所有患者中都引起了明显的恶心和呕吐。在氮芥治疗后被判定为“治疗失败”的4例患者中,有3例在单次剂量的短小棒状杆菌治疗后胸腔积液再积聚完全得到抑制,第4例患者生存期过短,无法充分评估其反应。短小棒状杆菌治疗组无治疗失败病例。短小棒状杆菌似乎是治疗复发性胸腔积液的一种有效且耐受性良好的药物。其强大的免疫刺激作用对其作用方式的相对贡献仍不确定。